298 related articles for article (PubMed ID: 24224472)
21. The group I metabotropic glutamate receptor antagonist S-4-CPG modulates the locomotor response produced by the activation of D1-like, but not D2-like, dopamine receptors in the rat nucleus accumbens.
David HN; Abraini JH
Eur J Neurosci; 2001 Jun; 13(11):2157-64. PubMed ID: 11422457
[TBL] [Abstract][Full Text] [Related]
22. [Metabotropic glutamate receptors as targets for new drug development].
Arkhipov VI; Kapralova MV
Eksp Klin Farmakol; 2011; 74(10):46-52. PubMed ID: 22238988
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of the actions of group I metabotropic glutamate receptor subtype selective ligands on excitatory amino acid release and sodium-dependent re-uptake in rat cerebrocortical minislices.
Fazal A; Parker F; Palmer AM; Croucher MJ
J Neurochem; 2003 Sep; 86(6):1346-58. PubMed ID: 12950444
[TBL] [Abstract][Full Text] [Related]
24. An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors.
Bruno V; Battaglia G; Copani A; Cespédes VM; Galindo MF; Ceña V; Sánchez-Prieto J; Gasparini F; Kuhn R; Flor PJ; Nicoletti F
Eur J Neurosci; 2001 Apr; 13(8):1469-78. PubMed ID: 11328342
[TBL] [Abstract][Full Text] [Related]
25. The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Johnson KA; Jones CK; Tantawy MN; Bubser M; Marvanova M; Ansari MS; Baldwin RM; Conn PJ; Niswender CM
Neuropharmacology; 2013 Mar; 66():187-95. PubMed ID: 22546615
[TBL] [Abstract][Full Text] [Related]
26. Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.
Mercier MS; Lodge D
Neurochem Res; 2014 Oct; 39(10):1876-94. PubMed ID: 25146900
[TBL] [Abstract][Full Text] [Related]
27. Glutamate metabotropic receptors as targets for drug therapy in epilepsy.
Moldrich RX; Chapman AG; De Sarro G; Meldrum BS
Eur J Pharmacol; 2003 Aug; 476(1-2):3-16. PubMed ID: 12969743
[TBL] [Abstract][Full Text] [Related]
28. Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation.
Thomas AG; Olkowski JL; Slusher BS
Eur J Pharmacol; 2001 Aug; 426(1-2):35-8. PubMed ID: 11525768
[TBL] [Abstract][Full Text] [Related]
29. Metabotropic glutamate receptors in neurodegeneration/neuroprotection: still a hot topic?
Caraci F; Battaglia G; Sortino MA; Spampinato S; Molinaro G; Copani A; Nicoletti F; Bruno V
Neurochem Int; 2012 Sep; 61(4):559-65. PubMed ID: 22306345
[TBL] [Abstract][Full Text] [Related]
30. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat.
Gilmour G; Broad LM; Wafford KA; Britton T; Colvin EM; Fivush A; Gastambide F; Getman B; Heinz BA; McCarthy AP; Prieto L; Shanks E; Smith JW; Taboada L; Edgar DM; Tricklebank MD
Neuropharmacology; 2013 Jan; 64():224-39. PubMed ID: 22884720
[TBL] [Abstract][Full Text] [Related]
31. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia.
Chaki S
Eur J Pharmacol; 2010 Aug; 639(1-3):59-66. PubMed ID: 20371240
[TBL] [Abstract][Full Text] [Related]
32. Modulation of metabotropic glutamate receptors as potential treatment for acute and chronic neurodegenerative disorders.
Lea PM; Faden AI
Drug News Perspect; 2003 Oct; 16(8):513-22. PubMed ID: 14668949
[TBL] [Abstract][Full Text] [Related]
33. Metabotropic glutamate receptors and cognition: From underlying plasticity and neuroprotection to cognitive disorders and therapeutic targets.
Hoglund BK; Carfagno V; Olive MF; Leyrer-Jackson JM
Int Rev Neurobiol; 2023; 168():367-413. PubMed ID: 36868635
[TBL] [Abstract][Full Text] [Related]
34. Group III metabotropic glutamate receptors as promising targets for neuroprotective therapy: Particular emphasis on the role of mGlu4 and mGlu7 receptors.
Domin H
Pharmacol Biochem Behav; 2022 Sep; 219():173452. PubMed ID: 36030890
[TBL] [Abstract][Full Text] [Related]
35. Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand.
Taylor DL; Jones F; Kubota ES; Pocock JM
J Neurosci; 2005 Mar; 25(11):2952-64. PubMed ID: 15772355
[TBL] [Abstract][Full Text] [Related]
36. Group-I metabotropic glutamate receptors: hypotheses to explain their dual role in neurotoxicity and neuroprotection.
Nicoletti F; Bruno V; Catania MV; Battaglia G; Copani A; Barbagallo G; Ceña V; Sanchez-Prieto J; Spano PF; Pizzi M
Neuropharmacology; 1999 Oct; 38(10):1477-84. PubMed ID: 10530809
[TBL] [Abstract][Full Text] [Related]
37. mGlu3 receptor and astrocytes: partners in neuroprotection.
Durand D; Carniglia L; Caruso C; Lasaga M
Neuropharmacology; 2013 Mar; 66():1-11. PubMed ID: 22564439
[TBL] [Abstract][Full Text] [Related]
38. Metabotropic glutamate receptors as therapeutic targets for schizophrenia.
Vinson PN; Conn PJ
Neuropharmacology; 2012 Mar; 62(3):1461-72. PubMed ID: 21620876
[TBL] [Abstract][Full Text] [Related]
39. Group II and group III metabotropic glutamate receptor agonists depress synaptic transmission in the rat spinal cord dorsal horn.
Gerber G; Zhong J; Youn D; Randic M
Neuroscience; 2000; 100(2):393-406. PubMed ID: 11008177
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
